Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 88

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 88
---

will have up to 15 months to consummate an initial business combination (April 29, 2026) from the closing of the IPO (which may be extended
without shareholder approval up to two times, each by an additional three months (for a total of up to 21 months to complete an initial
business combination from the closing of the IPO), subject to the sponsor depositing into the trust account $0.10 per public share outstanding
in connection with each such extension). If we are unable to consummate an initial business combination within such time period, we will
redeem 100% of the issued and outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate
amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of funds withdrawn
to pay our taxes, if any, and up to $100,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding
public shares, subject to applicable law, and then seek to liquidate and subsequently dissolve.

20

We
will provide our public shareholders with the opportunity to redeem all or a portion of their public shares upon the completion of our
initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account
calculated as of two business days prior to the consummation of the initial business combination, including interest (net of funds withdrawn
to pay our taxes, if any), divided by the number of then issued and outstanding public shares, subject to certain limitations. Our public
shareholders will be permitted to redeem their shares regardless of whether they abstain, vote for, vote against, or vote at all with
respect to the proposed business combination. There will be no redemption rights upon the completion of our initial business combination
with respect to our rights. Our sponsor, directors and officers have entered into a letter agreement with us, pursuant to which they
have agreed to waive their redemption rights with respect to any shares held by them in connection with the completion of our initial
business combination.

If
a shareholder vote on our initial business combination is not required by law and we do not decide to hold a shareholder vote for business
or other legal reasons, we will offer to redeem our public shares pursuant to Rule 13e-4 and Regulation 14E under the Exchange Act, and
will file tender offer documents with the SEC prior to completing our